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selective neurons in the striatum and cortex (1, 2). Although
HD is known to be caused by abnormal expansion of polyglutamine repeats in huntingtin (Htt) (3), how the toxic mutant
protein drives neuronal dysfunction and death remains poorly
understood, and currently, no disease-modifying treatment
exists for this disease. Transcriptional dysregulation is an early
abnormality in the course of HD progression and has been suggested to play an important role in HD pathogenesis (4 –6).
However, how mutant Htt induces transcriptional alterations
and the identity of functionally relevant genes, which contribute to neuronal death, remain largely unknown.
Several potential mechanisms have been proposed to underlie transcriptional dysregulation in HD neurons, including
altered activities of transcription factors, coactivators, or
corepressors by aberrant binding to or sequestration by
mutant Htt protein (4, 7–10). More recently, studies using
cell and mouse models of HD have shown that mutant
Htt expression may modify chromatin structure via perturbations in several epigenetic pathways, including DNA
methylation, histone acetylation, and histone H3 lysine 4
trimethylation (H3K4me3), through mechanisms that are
incompletely understood (11–16). The direct binding of
mutant Htt to genomic DNA may also affect gene expression
(17). These mechanisms may not be mutually exclusive and
may cooperate to induce transcriptional alterations observed in HD. However, which mechanisms are dominant in
HD neurodegeneration remains unknown.
DNA methylation (5-methylcytosine) at CpG sites is
a well-characterized epigenetic modification catalyzed by
DNA methyltransferases (DNMTs), and hypermethylation
of gene promoters generally triggers gene silencing (18 –20).
Dysregulation of DNA methylation has recently been demonstrated in cell and mouse models of HD (12, 21, 22). Our recent
study showed that both pharmacological and genetic inhibition
of DNMTs dramatically protect primary cortical and striatal
neurons from mutant Htt–induced cytotoxicity (21). Moreover, DNMT inhibition in culture or mouse models of HD restitative PCR and RT-PCR, respectively; NF, neurofilament; TSS, transcription
start site; BDNF, brain-derived neurotrophic factor; FdCyd, 5-fluoro-2⬘deoxycytidine; MeDIP, methylated DNA immunoprecipitation; 5-mC,
5-methylcytosine; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; IP, immunoprecipitation; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ANOVA, analysis of variance.
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Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by an abnormal expansion of polyglutamine repeats
in the huntingtin protein (Htt). Transcriptional dysregulation is
an early event in the course of HD progression and is thought to
contribute to disease pathogenesis, but how mutant Htt causes
transcriptional alterations and subsequent cell death in neurons
is not well understood. RNA-Seq analysis revealed that expression of a mutant Htt fragment in primary cortical neurons leads
to robust gene expression changes before neuronal death. Basic
helix-loop-helix transcription factor Twist1, which is essential
for embryogenesis and is normally expressed at low levels in
mature neurons, was substantially up-regulated in mutant Htt–
expressing neurons in culture and in the brains of HD mouse
models. Knockdown of Twist1 by RNAi in mutant Htt–
expressing primary cortical neurons reversed the altered
expression of a subset of genes involved in neuronal function
and, importantly, abrogated neurotoxicity. Using brain-derived
neurotrophic factor (Bdnf), which is known to be involved in HD
pathogenesis, as a model gene, we found that Twist1 knockdown
could reverse mutant Htt–induced DNA hypermethylation at
the Bdnf regulatory region and reactivate Bdnf expression.
Together, these results suggest that Twist1 is an important
upstream mediator of mutant Htt–induced neuronal death and
may in part operate through epigenetic mechanisms.

Role of Twist1 in mutant huntingtin– expressing neurons

Results
Mutant Htt induces marked transcriptional changes in
primary cortical neurons
HD brain pathology primarily involves the striatum and cerebral cortex. Studies with HD patients and animal models demonstrate progressive atrophy of the cerebral cortex and dysfunction of corticostriatal synapses (1, 41– 44), highlighting the
important contribution of cortical neuron dysfunction in HD.
We previously described a physiologically relevant primary
cortical neuron model of HD (21, 45). In this system, a neuropathogenic fragment of mutant Htt, the exon 1– encoded
N-terminal fragment with a 72-polyglutamine (polyQ) repeat
(Htt-72Q), versus WT Htt with a 25-polyQ repeat (Htt-25Q), is
expressed in mouse primary cortical neurons by lentivirus
(Fig. 1A). In contrast to the diffuse cytosolic localization of
WT Htt, accumulation of aggregated mutant Htt was
observed preferentially in the nucleus by immunofluorescence (Fig. 1B). Consistently, immunoblot analysis with Htt72Q– expressing neurons showed aggregated high-molecu-

lar weight mutant protein (Fig. 1C). Our previous studies
have shown that expression of mutant, but not WT, Htt significantly reduced neuronal viability compared with that of
control empty vector (21, 45).
To identify critical gene expression changes associated with
mutant Htt expression in neurons, RNA-Seq analysis was performed using RNA samples prepared from cortical neurons at 5
days following Htt virus infection (DIV 10), a time when neurons do not yet show mutant Htt–induced changes in viability
(Fig. 1D). We identified marked transcriptional changes, with
1391 up-regulated and 2314 down-regulated genes (FDR ⬍
0.05), in mutant Htt-72Q– expressing neurons compared with
WT Htt-25Q– expressing neurons (Fig. 1E and Table S1). The
transcriptome of Htt-25Q– expressing neurons was not significantly different from control neurons transduced with emptyvector lentivirus (Fig. 1E). To gain insight into pathways that
are potentially affected by mutant Htt, we performed gene
ontology (GO) enrichment analyses using the DAVID functional classification tool (Fig. 1, F and G) (46). The differentially
expressed genes in mutant Htt– expressing cortical neurons
(兩log2FC兩 ⬎ 0.5, FDR ⬍ 0.05) were associated with a number of
specific biological processes and molecular function (Fig. 1 (F
and G) and Table S2). In particular, up-regulated genes were
associated with biological processes, including regulation of
transcription, and down-regulated genes were associated with
biological processes relevant to brain and nervous system function, including nervous system development, axon guidance,
cell adhesion, and synaptic transmission (Fig. 1F). Molecular
function analysis revealed that up-regulated genes were
enriched in genes encoding transcriptional regulators, including sequence-specific DNA binding, transcriptional activator
activity, and transcriptional factor activity (Fig. 1G). Down-regulated genes are enriched in genes related to calcium ion binding and ion channel activity (Fig. 1G). These results raise the
interesting possibility that altered levels of transcriptional regulators represent an early event in the transcriptional dysregulation observed in mutant Htt– expressing neurons.
We next examined whether gene expression changes found
in our cortical neuron system were observed in mouse and
human HD brains in vivo in a previous study (11, 47, 48). Htt72Q– expressing mouse primary cortical neurons and the cortex of R6/2 HD transgenic mice (11) shared 323 down-regulated and 45 up-regulated genes (FDR ⬍ 0.05) (Table S3).
In addition, we found substantial overlap in differentially
expressed genes between the Htt-72Q– expressing primary
cortical neurons (FDR ⬍ 0.05) and human HD cortex in previous RNA-profiling studies: 286 down-regulated and 200 upregulated genes in human HD prefrontal cortex (Brodmann
area 9) from Vonsattel grade 3 and 4 HD patients (RNA-Seq
analysis, FDR ⬍ 0.05) (47) and 175 down-regulated and 19 upregulated genes in human HD frontal cortex (Brodmann area 4)
from low Vonsattel grade 0 –2 patients (microarray analysis,
p ⬍ 0.001) (48) (Table S4). The differentially expressed genes in
our neuron culture system also contain novel gene expression
changes, which might represent potential candidates for neuron-specific changes missed in previous RNA profiling studies
due to the presence of multiple cell types or loss of neurons in
brain tissue. The top 30 down- and up-regulated genes (FDR ⬍
J. Biol. Chem. (2018) 293(30) 11850 –11866
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cued the expression of key down-regulated genes, which are
also decreased in the brains of HD patients, including brainderived neurotrophic factor (Bdnf) and striatum-enriched
genes, such as Ppp1r1b, Drd2, Adora2a, and Rasd2 (21). BDNF
is a major neurotrophic factor involved in a number of fundamental processes in the brain, including neuronal survival, synaptic plasticity, and learning and memory (23, 24). The reduced
expression of Bdnf in the brain of HD patients and mouse models has been suggested to play a critical role in HD pathogenesis
(23, 25–27). Indeed, restoration of BDNF in cell and mouse
models has been shown to improve HD phenotypes (21, 25,
28 –31). Consistent with the inhibition of Bdnf expression,
mutant Htt– expressing cortical neurons showed increased levels of Bdnf promoter methylation (21). These observations
strongly suggest that aberrant DNA methylation plays a functionally important role in HD neurons.
N-terminal fragments of mutant Htt, including mutant Htt
exon-1 protein, are known to be more cytotoxic and prone to
aggregation compared with the full-length protein and are
expressed in brains of HD patients (32–37). These fragments
can be generated by proteolytic cleavage of the full-length protein in cells (33–38). It has also recently been demonstrated that
mutant Htt exon-1 fragment can be generated by abnormal
alternative splicing in HD (32).
In this report, we identify mutant Htt (exon 1)–induced
genome-wide transcriptome changes in cortical neurons, a vulnerable neuronal type in HD. Among altered genes, we focused
on basic helix-loop-helix (bHLH) transcription factor Twist1,
which is significantly up-regulated by mutant Htt expression in
neurons. Whereas the function of Twist1 has been well studied
in embryogenesis and cancer metastasis (39, 40), its role in neurodegeneration has not been explored. Here we demonstrate
that Twist1 plays a causal role in mutant Htt–induced cytotoxicity in neurons and provide evidence that Twist1 alters neuronal gene expression in HD potentially through epigenetic regulation, providing new insight into the function of Twist1 in
postmitotic neurons.

Role of Twist1 in mutant huntingtin– expressing neurons
0.05, average counts per million (CPM) ⬎ 0.5) from the total
3705-differentially expressed gene set identified in the primary
neuron system are listed (Table 1). Together, these results demonstrate that the neuropathogenic Htt fragment induces cellintrinsic gene expression changes, which recapitulate expression changes in the mouse and human HD brain in vivo.

Mutant Htt triggers up-regulation of multiple transcription
factors in cortical neurons
As shown by GO analysis (Fig. 1 (F and G) and Table S2), the
up-regulated genes in mutant Htt– expressing cortical neurons
were enriched in genes encoding transcriptional regulators.
These results suggest that aberrant expression of these factors
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Increased Twist1 expression in HD in vivo
Twist1 is a bHLH transcription factor that is known to play
an important role during development and in cancer, but its
role in postmitotic neurons is unknown. In addition to the primary neuron system, marked elevation of Twist1 mRNA has
also been observed in the cortex of HD patients in recent RNAprofiling analyses (47). We additionally verified this increase in
Twist1 expression in the brains of two different HD mouse

models: in the forebrain of early disease stage (6-week-old) R6/2
mice expressing the N-terminal exon-1 fragment of mutant Htt
(55) and in the cortex and striatum of zQ175 knock-in mice
expressing full-length mutant Htt (56) (Fig. 3, A–C). The
increase of Twist1 transcript in these mouse models was
observed in the context of decreased levels of cortical early
growth response 3 (Egr3) and Bdnf and striatal Drd2 and
Ppp1r1b transcripts, which are known to be down-regulated in
patients and mouse models of HD (Fig. 3, A–C). zQ175
homozygous mice showed a higher degree of alterations in
these transcripts compared with heterozygous littermates (Fig. 3,
B and C). Consistent with the elevated RNA expression, increased
Twist1 protein levels were observed in HD mice by immunoblotting using early to mid-stage R6/2 forebrain (Fig. 3D). Together,
these results support the idea that elevated Twist1 expression in
neurons might play a role in HD pathogenesis.
Twist1 is required for mutant Htt–induced neurotoxicity
To understand the role of Twist1 in mutant Htt–induced
neurotoxicity, we next tested whether decreased Twist1
expression by lentivirus-mediated RNAi can attenuate cell
death in our cortical neuron model of HD. Along with Twist1,
we tested the effect of Pou4f1 RNAi because Pou4f1, like
Twist1, is up-regulated not only in our neuron culture system
but also in vivo in the brains of human and mouse HD (Table 1
and Tables S1, S3, and S4) (11, 47, 48, 57). Validation experiments using quantitative RT-PCR (qRT-PCR) confirmed
increased levels of Twist1 and Pou4f1 mRNA in mutant Htt–
expressing cortical neurons (Fig. 4, A and B). Consistently,
immunoblot analysis demonstrated increased levels of endogenous Twist1 protein by mutant Htt (Fig. 4C). The efficient
reduction of Twist1 protein and RNA by two different Twist1
shRNAs was confirmed in mutant Htt-72Q– expressing neurons (Fig. 4, C and D). Remarkably, Twist1 RNAi increased the
viability of mutant Htt-72Q– expressing neurons to that of Htt25Q– expressing neurons (Fig. 4E). To demonstrate the specificity of the Twist1 RNAi phenotype, we performed a rescue
experiment using a mutant Twist1 cDNA (herein Twist1-Res),
which harbors nine-base mismatches within the sequence targeted by Twist1 RNAi 2, rendering it insensitive to the RNAi.
The neuroprotection conferred by Twist1 knockdown in Htt72Q– expressing neurons was reversed by co-expression of
Twist1-Res, demonstrating the specificity of the Twist1 RNAi
phenotype (Fig. 4F). These results suggest that Twist1 plays an

Figure 1. Mutant Htt triggers transcriptional dysregulation in primary cortical neurons. A, mouse primary cortical neuron model of HD. The N-terminal
exon-1 fragment of mutant Htt (Htt-72Q) or WT Htt (Htt-25Q) was lentivirally expressed in primary cortical neurons. A timeline of experiments using this culture
system is shown. B, primary cortical neurons transduced with Htt lentivirus as in A were fixed at 9 days postinfection and subjected to immunofluorescence with
anti-Htt antibody. Nuclei were labeled with Hoechst 33342. Bar, 100 m. C, primary cortical neurons transduced with Htt-expressing lentivirus as in A were
directly harvested in SDS sample buffer at 7 days postinfection. The whole-cell lysates were subjected to immunoblotting with anti-Htt antibody. Blot was
reprobed with anti-␤-actin antibody. Htt-72Q– expressing neurons showed aggregated high-molecular weight mutant Htt in a stacking gel (*). D, primary
cortical neurons transduced with Htt– expressing lentivirus as in A were subjected to MTS assay at 5, 7, and 9 days postinfection. MTS-reducing activity was
normalized to Htt-25Q lentivirus (⫽ 1) for each time point. Htt-72Q– expressing neurons showed progressive neuronal death. Significantly decreased cell
viability was observed at 7 and 9 days, but not 5 days, postinfection (unpaired t test; *, p ⬍ 0.0001 compared with Htt-25Q, n ⫽ 10 –15). Data represent mean ⫹
S.E. (error bars). E, RNA was harvested from primary cortical neurons infected with Htt-25Q–, Htt-72Q–, or control empty vector– expressing lentivirus at 5 days
postinfection as in A and subjected to RNA-Seq analysis. Cultures from four independent experiments were used. MA plots show log2FC against log2CPM, and
each dot represents a gene. Red dots represent differentially expressed genes, 1391 up- and 2314 down-regulated genes (FDR ⬍ 0.05), in Htt-72Q– expressing
neurons compared with Htt-25Q– expressing neurons (left). RNA expression in Htt-25Q– expressing neurons was not significantly different from that of control
vector (right). FC, -fold change. F and G, GO enrichment analyses of differentially expressed genes obtained by RNA-Seq analysis with the primary cortical
neuron model of HD. Top-enriched GO biological processes (F) and molecular function (G) for up-regulated genes (log2FC ⬎ 0.5, FDR ⬍ 0.05) and downregulated (log2FC ⬍ 0.5, FDR ⬍ 0.05) in Htt-72Q-expressing neurons were determined using DAVID bioinformatics resources. A complete list of GO terms can
be found in Table S2.
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might further amplify the ongoing transcriptional dysregulation in mutant Htt– expressing neurons. We found that genes
encoding transcription factors, including forkhead box D1
(Foxd1), POU domain, class 4, transcription factor 1 (Pou4f1 or
Brn3a), Twist1, and several homeobox genes, such as Hoxd8,
Hoxb9, and LIM homeobox 4 (Lhx4), are substantially up-regulated in mutant Htt–expressing cortical neurons (Table 1). Interestingly, these highly up-regulated transcription factors are known
to play a critical role in cell fate determination and/or differentiation during embryonic development (39, 40, 49–53).
To better understand the molecular pathways underlying
mutant Htt–induced neurotoxicity, we performed higher-order transcriptional regulatory network analysis of the whole
transcriptome data as described previously (54) and identified
gene regulatory pathways that are specific to mutant Htt. The
core regulatory network was assembled using the knowledgebased GeneGO MetaCore database from 1217 differentially
expressed genes between Htt-72Q– and Htt-25Q– expressing
cortical neurons in RNA-Seq analysis (genes with FDR ⬍ 0.05,
兩log2FC兩 ⬎ 1, and average CPM ⬎ 0.5 from Table S1) and was
composed of 13 transcription factors (TFs) (兩log2FC兩 ⬎ 1.5) that
interact with one or more TFs and 20 target genes that are
regulated by at least two of the 13 TFs, with a total of 77 interactions (Fig. 2 and Table S5). The network analysis provided
potential transcription factors and targets that may be involved
in mutant Htt–induced neurotoxicity. In particular, up-regulated transcription factors Ar, Twist1, Wt1, and Tal1 exhibit a
high number of interactions with other genes in the network
(Fig. 2 and Table S5), suggesting that these factors may be
important upstream transcriptional regulators associated with
mutant Htt. Among these genes, the levels of Twist1 transcript
were most robustly altered in Htt-72Q– expressing neurons:
12.6-fold compared with Htt-25Q– expressing neurons (Table
1 and Table S1), suggesting a critical contribution of Twist1 to
mutant Htt–induced gene expression changes.

Role of Twist1 in mutant huntingtin– expressing neurons
Table 1
Top up- and down-regulated genes in mutant Htt–expressing primary cortical neurons
Top 30 up- and down-regulated genes (FDR ⬍ 0.05, average CPM ⬎ 0.5) in Htt-72Q– versus Htt-25Q–expressing cortical neurons identified by RNA-Seq analysis are
shown. The entire list of differentially expressed genes (FDR ⬍ 0.05) is found in Table S1.
Ensembl gene ID

Gene symbol

-Fold change

FDR

Gene biotype

Hoxd8
Shox2
Irs4
Foxd1
Rhd
Hoxb9
Pou4f1
Lhx4
Rcsd1
Ccer2
Vax2
Hoxb13
Isl2
Pou4f3
Grhl3
Cdkn2a
Pgr15l
Ebf3
Gm13572
AW551984
Plcz1
Arhgef16
Acp7
Ripk4
Twist1
Foxf1
Epha2
Arf4os
Mecom
Tal1

95.0
58.8
37.1
35.8
33.3
32.5
29.2
27.9
25.3
22.6
22.2
21.4
18.8
17.2
17.0
16.6
16.5
16.4
15.9
14.3
13.5
13.3
13.1
13.0
12.6
11.9
11.1
11.0
9.8
9.7

1.30E ⫺ 07
6.18E ⫺ 08
1.39E ⫺ 05
2.30E ⫺ 06
2.80E ⫺ 04
1.18E ⫺ 05
2.01E ⫺ 06
5.57E ⫺ 06
2.61E ⫺ 05
6.47E ⫺ 05
3.87E ⫺ 05
8.09E ⫺ 05
1.55E ⫺ 05
7.06E ⫺ 04
1.84E ⫺ 03
6.54E ⫺ 05
8.52E ⫺ 06
1.98E ⫺ 06
1.84E ⫺ 04
2.42E ⫺ 09
1.81E ⫺ 04
2.13E ⫺ 03
5.51E ⫺ 03
3.03E ⫺ 05
4.65E ⫺ 06
9.65E ⫺ 04
2.50E ⫺ 03
4.66E ⫺ 03
1.09E ⫺ 02
3.69E ⫺ 08

protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
lincRNA
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
antisense_RNA
protein_coding
protein_coding

Down-regulated genes
ENSMUSG00000070719
ENSMUSG00000046922
ENSMUSG00000085905
ENSMUSG00000078958
ENSMUSG00000048776
ENSMUSG00000039059
ENSMUSG00000013846
ENSMUSG00000027435
ENSMUSG00000078945
ENSMUSG00000032128
ENSMUSG00000043932
ENSMUSG00000038530
ENSMUSG00000090061
ENSMUSG00000032033
ENSMUSG00000097892
ENSMUSG00000084946
ENSMUSG00000026344
ENSMUSG00000042351
ENSMUSG00000097182
ENSMUSG00000046808
ENSMUSG00000027401
ENSMUSG00000021765
ENSMUSG00000063260
ENSMUSG00000044447
ENSMUSG00000092569
ENSMUSG00000027400
ENSMUSG00000014782
ENSMUSG00000050157
ENSMUSG00000035357
ENSMUSG00000037362

Pla2g4d
Gpr6
Gm14273
Atp6ap1l
Pthlh
Hrh3
St3gal1
Cd93
Naip2
Robo3
Klri2
Rgs4
Nwd2
Barx2
Gm26801
Dlx1as
Lypd1
Grap2
A830009L08Rik
Atp10d
Tgm3
Fst
Syt10
Dock5
Gm20544
Pdyn
Plekhg4
Gm867
Pdzrn3
Nov

0.02
0.05
0.06
0.07
0.08
0.09
0.10
0.10
0.10
0.11
0.11
0.11
0.11
0.12
0.13
0.13
0.13
0.13
0.13
0.13
0.13
0.13
0.13
0.14
0.14
0.14
0.14
0.14
0.14
0.14

1.43E ⫺ 07
4.65E ⫺ 08
3.66E ⫺ 05
9.02E ⫺ 05
3.68E ⫺ 05
1.66E ⫺ 07
1.16E ⫺ 07
6.80E ⫺ 05
3.65E ⫺ 04
1.58E ⫺ 05
5.92E ⫺ 04
3.49E ⫺ 09
1.96E ⫺ 09
5.67E ⫺ 06
1.28E ⫺ 03
2.37E ⫺ 02
1.13E ⫺ 07
1.36E ⫺ 03
2.75E ⫺ 04
7.51E ⫺ 07
1.14E ⫺ 06
1.85E ⫺ 05
6.39E ⫺ 08
4.91E ⫺ 07
6.60E ⫺ 03
9.62E ⫺ 03
3.88E ⫺ 03
3.59E ⫺ 04
3.18E ⫺ 08
1.96E ⫺ 09

protein_coding
protein_coding
antisense_RNA
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
antisense_RNA
antisense_RNA
protein_coding
protein_coding
lincRNA
polymorphic_pseudogene
protein_coding
protein_coding
protein_coding
protein_coding
processed_transcript
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding

important role in mutant Htt–induced neuronal death. By contrast, knockdown of Pou4f1 did not protect neurons against
Htt-72Q–induced toxicity and in fact decreased the viability of
Htt-25Q–expressing neurons (Fig. 4, G and H). These results suggest that Pou4f1 is required for the survival of normal cortical neurons and that up-regulation of this transcription factor by mutant
Htt may represent a compensatory mechanism.
We further tested whether Twist1 RNAi is neuroprotective
against mutant Htt–induced neurite degeneration by quantify-

11854 J. Biol. Chem. (2018) 293(30) 11850 –11866

ing the loss of neurofilament (NF) immunofluorescence intensity, an early marker of neuronal toxicity (21, 58). Consistent
with its effect on cell viability, Twist1 RNAi abrogated neurite
degeneration in mutant Htt– expressing neurons (Fig. 4I).
Moreover, using an alternative cytotoxicity assay, Sytox Green
dead cell stain, we also showed that Twist1 RNAi blocks mutant
Htt–induced cell death (Fig. 4J).
Gene expression is regulated by the coordination of epigenetic and transcriptional regulators. Consistent with its

Downloaded from http://www.jbc.org/ at Washington University on November 20, 2019

Up-regulated genes
ENSMUSG00000027102
ENSMUSG00000027833
ENSMUSG00000054667
ENSMUSG00000078302
ENSMUSG00000028825
ENSMUSG00000020875
ENSMUSG00000048349
ENSMUSG00000026468
ENSMUSG00000040723
ENSMUSG00000096257
ENSMUSG00000034777
ENSMUSG00000049604
ENSMUSG00000032318
ENSMUSG00000024497
ENSMUSG00000037188
ENSMUSG00000044303
ENSMUSG00000031212
ENSMUSG00000010476
ENSMUSG00000085975
ENSMUSG00000038112
ENSMUSG00000030230
ENSMUSG00000029032
ENSMUSG00000037469
ENSMUSG00000005251
ENSMUSG00000035799
ENSMUSG00000042812
ENSMUSG00000006445
ENSMUSG00000090861
ENSMUSG00000027684
ENSMUSG00000028717

Role of Twist1 in mutant huntingtin– expressing neurons

increased RNA expression, the regulatory regions of Twist1
around the transcription start site (TSS) showed increased
levels of an active histone mark, H3K4me3, in mutant
Htt– expressing cortical neurons compared with WT Htt–
expressing neurons by ChIP-qPCR (Fig. 4K). These data suggest that an increase in this histone modification contributes to
the up-regulation of Twist1 downstream of mutant Htt.
Together, these results demonstrate that Twist1 is essential for
mutant Htt–induced neuronal death.
Identification of Twist1-dependent genes in mutant
Htt– expressing neurons
Twist1 can act as an activator or repressor of transcription by
specific interactions with other transcriptional regulators or
chromatin modifiers (39, 40, 59). Because Twist1 RNAi protected neurons against mutant Htt–induced toxicity (Fig. 4, E
and I), we hypothesized that Twist1 induces a transcriptional
program that leads to neuronal death in mutant Htt–
expressing neurons, potentially by altering expression of
genes relevant for neuronal function and survival. To identify the genes that are dysregulated by Twist1 in mutant Htt–
expressing neurons, we performed RNA-Seq analysis following Twist1 knockdown. The following four groups of
primary cortical neurons were subjected to RNA-Seq: 1)
Htt-25Q–expressing neurons with control shRNA, 2) Htt72Q– expressing neurons with control shRNA, 3) Htt-72Q–
expressing neurons with Twist1 shRNA 1, and 4) Htt-72Q–
expressing neurons with Twist1 shRNA 2. Through this
analysis, we identified 197 differentially expressed genes (143
down- and 54 up-regulated genes) in mutant Htt– expressing
neurons whose expression was rescued by two different Twist1
shRNAs (1 and 2) (Fig. 5 (A and B) and Table S6). As a positive

control, Twist1 was one of the 54 genes that are up-regulated by
mutant Htt and down-regulated by Twist1 RNAi (Fig. 5B).
These findings suggest that Twist1 is involved in the regulation
of a subset of genes downstream of mutant Htt. Among the 196
Twist1-dependent genes altered by mutant Htt (Fig. 5, A and B),
55 genes (49 down- and 6 up-regulated genes), which were also
differentially expressed in one or more of the previous in vivo
RNA profiling analyses with human and mouse HD cortices
(11, 47, 48, 57) and therefore potential Twist1-dependent
genes in vivo, were selected (Fig. 5C). Among these filtered
genes, we validated two Twist1-dependent genes, Egr3 and
Egr4, by qRT-PCR (Fig. 5D).
bHLH transcription factors, including Twist1, form homodimers or heterodimers and bind specific DNA sequences
known as E-boxes (consensus sequence: CANNTG) in the promoters of target genes (60, 61). To identify potential direct
Twist1 targets among the Twist1-dependent deregulated genes
in mutant Htt– expressing neurons (143 down- and 53 up-regulated genes in Fig. 5 (A and B)), we searched for genes harboring known Twist-binding motifs (MA0633.1, Twist2 from the
JASPAR CORE database, and FIMO) (62, 63). We examined
both down- and up-regulated genes as Twist1 can activate or
repress gene expression. De novo motif analysis of the
sequences covering ⫾2 kb of the TSS of the 196 Twist1-dependent genes revealed enrichment of Twist-binding sites, with
157 putative Twist-binding sites in 87 Twist1-dependent
deregulated (63 down- and 24 up-regulated) genes (Fig. 5E and
Table S7).
We found that a greater proportion of genes are repressed
than activated by Twist1 in mutant Htt– expressing neurons
(Fig. 5, A and B). KEGG pathway analysis showed that the
J. Biol. Chem. (2018) 293(30) 11850 –11866
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Figure 2. Transcriptional regulatory network of mutant Htt– expressing cortical neurons. A mutant Htt–associated transcriptional network was generated from differentially expressed genes (FDR ⬍ 0.05, average CPM ⬎ 0.5) identified by RNA-Seq analysis with the primary cortical neuron model of HD, using
GeneGo MetaCore as described under “Experimental procedures.” 77 interactions with 13 transcription factors (oval, 兩log2FC兩 ⬎ 1.5) and 20 targets (box,
兩log2FC兩 ⬎ 1) are shown. The connections between genes represent transcriptional regulation, protein binding, or posttranslational modification (phosphorylation). Color denotes log2FC. See also Table S5.
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Knockdown of Twist1 restores normal Bdnf expression and
promoter methylation in a primary neuron model of HD

Figure 3. Increased Twist1 gene expression in mouse models of HD. A,
qRT-PCR analysis was performed using RNA prepared from 6-week-old R6/2
HD and control WT mouse forebrains (n ⫽ 6 (3 males, 3 females)/group).
␤-actin and Hprt were used as reference genes. Twist1 RNA was up-regulated
in R6/2 compared with WT mice (unpaired t tests; *, p ⫽ 0.0043). Egr3 and Bdnf
(exon IX, protein coding) RNAs were down-regulated in R6/2 compared
with WT mice (unpaired t tests; *, p ⫽ 0.0013 for Egr3; *, p ⫽ 0.022 for Bdnf).
B and C, qRT-PCR analysis was performed using RNA prepared from
33-week-old zQ175 heterozygous (Het), homozygous (Homo), and control
WT mouse cortex (B) and striatum (C) (n ⫽ 6 (3 males and 3 females) for
zQ175 heterozygous and homozygous; n ⫽ 7 (4 males and 3 females) for
WT). Twist1 RNA was up-regulated in the cortex and striatum of zQ175
mice compared with those of WT (ANOVA; *, p ⫽ 0.0001 in B; *, p ⫽ 0.0007
in C). Egr3 and Bdnf (exon IX, protein coding) RNAs were down-regulated
in the cortex of zQ175 compared with WT mice (ANOVA; *, p ⫽ 0.042; #, p ⫽
0.011 for Egr3; *, p ⫽ 0.047 for Bdnf) (B). Drd2 mRNA was down-regulated in
zQ175 striatum compared with WT control (ANOVA; *, p ⫽ 0.014) (C). A
trend toward decreased expression of Ppp1r1b in zQ175 mice (zQ175
homozygous compared with WT; p ⫽ 0.063) (C). D, immunoblot analysis
(IB) was performed using forebrain lysates prepared from 9-week-old R6/2
HD and control WT mice (n ⫽ 6 (3 males, 3 females)/group). Twist1 band
intensity was quantified by densitometry (ImageJ) and normalized to that
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BDNF is an important trophic factor involved in a wide variety of neuronal functions in development as well as in the
mature nervous system, and the abnormal reduction of Bdnf
mRNA and protein has been implicated in HD pathogenesis
(23, 26, 27). The human and rodent Bdnf genes have a complex
genomic structure composed of at least eight different noncoding exons and a common coding exon (71, 72). Distinct Bdnf
transcripts consisting of a different 5⬘-UTR exon linked by the
coding exon are driven by specific promoters but generate the
same protein. We previously showed that Bdnf transcripts containing exons IV and VI (hereafter Bdnf IV and VI transcripts)
are specifically down-regulated by mutant Htt in cultured cortical neurons (21). Down-regulation of the Bdnf IV and VI transcripts has also been observed in human and mouse HD brain
(23, 26, 73), suggesting that dysregulation of these transcripts is
relevant for reduction of BDNF in HD. We therefore tested the
possibility that Twist1 might dysregulate Bdnf IV and VI transcripts in mutant Htt– expressing cortical neurons (Fig. 6A).
Knockdown of Twist1 increased the levels of Bdnf IV and VI
transcripts by qRT-PCR analysis in mutant Htt– expressing
of GAPDH. Twist1 protein expression was increased in R6/2 compared
with WT mice (unpaired t tests; *, p ⬍ 0.0001). Data represent mean ⫹ S.E.
(error bars) in A–D.
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Twist1-dependent repressed genes in mutant Htt– expressing
neurons are significantly enriched in pathways relevant to neuronal function, including neuroactive ligand-receptor interaction, calcium signaling pathway, and cAMP signaling pathway
(Fig. 5F), suggesting that dysregulation of the Twist1 target
genes are important for neuronal function and thus may contribute to mutant Htt–induced neurotoxicity.
Transcription is coordinately regulated by a multiprotein
complex consisting of transcription factors and chromatin
modifiers, such as histone deacetylases and methyltransferases.
Several transcriptional and epigenetic regulators have also been
reported to interact and cooperate with Twist1 to control transcription of specific genes (40, 64 – 67). To gain insight into the
mechanism of Twist1-mediated transcriptional repression in
HD neurons, we searched for possible regulators of Twist1-dependent gene changes using Expression2Kinase (X2K) software
with the ChIP Enrichment Analysis (ChEA) database (68).
Interestingly, through this analysis, we found that core or regulatory components of polycomb repressive complex 2 (PRC2),
PRC1, and RE1 silencing transcription factor (REST) are potential regulators of Twist1-dependent repressed genes (Fig. 5G
and Table S8), raising the interesting possibility that these
repressors may be involved in Twist1-dependent transcriptional repression in mutant Htt– expressing neurons. PRC2 and
PRC1 are major epigenetic regulators and play important roles
in a wide range of biological processes in embryonic development and disease through silencing of target genes by modification of histones (69, 70). Together, our results demonstrated
that Twist1 is a key transcription factor driving abnormal
expression of a subset of genes and neurotoxicity in mutant
Htt– expressing neurons.
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neurons (Fig. 6A), suggesting that Twist1 represses these transcripts. These results are consistent with our RNA-Seq data,
where the decreased levels of Bdnf mRNA (total Bdnf transcripts) in mutant Htt-72Q– expressing neurons (0.71-fold of
Htt-25Q– expressing neurons) are restored by two different
Twist1 shRNAs (1.31- and 1.55-fold by Twist1 shRNAs 1 and 2,
respectively, compared with control shRNA) (Table S6).
Together, our results indicate that Twist1 contributes to the
reduction of Bdnf in HD neurons.
To understand the mechanism of Twist1-mediated repression of Bdnf, we considered our recent findings that mutant Htt
induces hypermethylation of the Bdnf promoter IV and causes
down-regulation of Bdnf IV transcript and that pharmacological inhibition of DNMTs blocks the mutant Htt–induced
increase in DNA methylation and subsequent neuronal death

(21). These observations raised the possibility that the Twist1dependent pathway may intersect with DNA methylation in
mutant Htt– expressing neurons. We first examined whether
mutant Htt–induced aberrant DNA methylation contributes to
up-regulation of Twist1. We asked whether DNMT inhibitor
5-fluoro-2⬘-deoxycytidine (FdCyd), which protects neurons
from mutant Htt–induced toxicity, could reverse the mutant
Htt–triggered increase in Twist1 mRNA (Fig. 6B). DNMT inhibition had little to no effect on Twist1 levels, suggesting that
abnormal DNA methylation does not cause Twist1 up-regulation (Fig. 6B). We next tested the possibility that Twist1 lies
upstream of aberrant mutant Htt–induced DNA methylation
and is necessary for the hypermethylation of Bdnf promoter IV
in mutant Htt– expressing cortical neurons. Methylated DNA
immunoprecipitation (MeDIP) experiments using anti-5Downloaded from http://www.jbc.org/ at Washington University on November 20, 2019
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methylcytosine (5-mC) antibody demonstrated that Twist1
knockdown blocks the mutant Htt–induced increase in promoter IV methylation (Fig. 6C), suggesting that Twist1 operates
upstream of DNA methylation–mediated gene repression.
Together, our findings suggest that mutant Htt causes
increased promoter methylation and repression of a specific
Bdnf transcript in cortical neurons in a Twist1-dependent manner (Fig. 6D).

Figure 4. Twist1 knockdown protects neurons from mutant Htt–induced toxicity in primary cortical neurons. A, DIV 5 cortical neurons were transduced
with Htt- or control (vector)-expressing lentivirus. Five days later, RNA was prepared and subjected to qRT-PCR using ␤-actin and Hprt as reference genes. Twist1
was up-regulated by Htt-72Q expression (ANOVA; *, p ⫽ 0.0083 compared with Htt-25Q, n ⫽ 3). B, qRT-PCR was performed using RNA prepared as in A. Pou4f1
was up-regulated by Htt-72Q expression (ANOVA; *, p ⬍ 0.0001 compared with Htt-25Q, n ⫽ 4). C, primary cortical neurons were transduced with Httexpressing lentivirus along with Twist1 shRNA (1 or 2) or control luciferase (Ctrl) shRNA lentivirus at DIV 5. Five days later, cell lysates were prepared and
subjected to immunoblotting (IB) with anti-Twist1 antibody. Blot was reprobed with anti-␤-actin antibody. Mutant Htt increased the levels of Twist1 protein.
Knockdown of Twist1 using two different shRNAs was confirmed. D, DIV 5 cortical neurons were transduced with Htt-72Q– expressing lentivirus along with
Twist1 shRNAs (1 or 2) or control luciferase (Ctrl) shRNA lentivirus. Five days later, RNA was prepared and subjected to qRT-PCR analysis. Twist1 RNAi reduced
the levels of Twist1 mRNA in mutant Htt– expressing neurons (ANOVA; *, p ⬍ 0.0001 compared with control RNAi, n ⫽ 6). E, DIV 5 cortical neurons co-transduced
as in C were subjected to an MTS assay at 9 days postinfection. Knockdown of Twist1 in mutant Htt– expressing neurons was neuroprotective (ANOVA; *, p ⬍
0.0001 compared with Htt-25Q neurons with control RNAi; #, p ⬍ 0.0001 compared with Htt-72Q neurons with control RNAi, n ⫽ 12–24). F, primary cortical
neurons were transduced with Twist1-Res lentivirus or control GFP lentivirus at DIV 4 and were co-transduced with Htt-72Q– expressing lentivirus along with
Twist1 shRNA 2 or control luciferase (Ctrl) shRNA lentivirus at DIV 5. Neurons were subjected to an MTS assay as in E. Expression of Twist1-Res reversed the
neuroprotection induced by Twist1 RNAi in Htt-72Q– expressing neurons (ANOVA; *, p ⫽ 0.0034 compared with GFP plus Twist1 RNAi, n ⫽ 6). G, qRT-PCR
analysis was performed using RNA prepared as in D. RNAi with three different Pou4f1 shRNAs (1, 2, and 3) reduced the levels of Pou4f1 mRNA in mutant
Htt– expressing neurons (ANOVA; *, p ⬍ 0.0001 compared with control RNAi, n ⫽ 3). H, primary cortical neurons transduced with Htt-expressing lentivirus along
with Pou4f1 shRNA (1, 2, or 3) or control shRNA lentivirus at DIV 5 were subjected to MTS assay as in E. Knockdown of Pou4f1 could not rescue mutant
Htt–induced toxicity (ANOVA; *, p ⬍ 0.0001 compared with Htt-25Q neurons with control RNAi; no increase in cell viability in Htt-72Q neurons with Pou4f1 RNAi
compared with control RNAi, n ⫽ 9 –15). Knockdown of Pou4f1 in Htt-25Q– expressing neurons decreased cell viability (ANOVA; #, p ⬍ 0.0001 compared with
Htt-25Q neurons with control RNAi, n ⫽ 9 –15). I, cortical neurons processed as in E were fixed at DIV 14 and subjected to NF immunofluorescence. Representative NF immunofluorescence images of transduced neurons are shown. Immunofluorescence intensity of images was quantified by an ImageJ-based macro.
Twist1 RNAi 2 blocked Htt-72Q–induced neurite degeneration (ANOVA; *, p ⬍ 0.0001 compared with Htt-25Q neurons with control RNAi; #, p ⬍ 0.0001
compared with Htt-72Q neurons with control RNAi, n ⫽ 15). J, DIV 5 cortical neurons co-transduced as in I were subjected to cell death assays using SYTOX
Green nuclear stain at 8 days postinfection. Total nuclei were labeled with Hoechst 33342. Representative staining images are shown. SYTOX Green-positive
dead cells as a fraction of Hoechst-positive cells were quantified using an ImageJ-based macro. Twist1 RNAi 2 blocked Htt-72Q–induced cell death (ANOVA; *,
p ⬍ 0.0001 compared with Htt-25Q neurons with control RNAi; #, p ⬍ 0.0001 compared with Htt-72Q neurons with control RNAi, n ⫽ 6). K, cortical neurons were
transduced as in A and 5 days later were subjected to ChIP with anti-H3K4me3 antibody. H3K4me3 levels at the regions around the TSS of Twist1 (promoter and
exon 1) were higher in Htt-72Q– expressing neurons compared with Htt-25Q neurons (unpaired t test; *, p ⬍ 0.0001 (promoter); *, p ⫽ 0.0030 (exon 1), n ⫽ 4).
Bar, 100 m (I and J). Data represent mean ⫹ S.E. (error bars) (A, B, and D–K).
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Discussion
Here, taking advantage of a mutant Htt– expressing primary
cortical neuron system and genome-wide RNA-Seq analysis,
we demonstrate that mutant Htt expression induces robust
transcriptional changes that overlap with changes observed in
brains of HD patients and mouse models. We find that bHLH
transcription factor Twist1 is substantially up-regulated by
mutant Htt in primary neurons, which is recapitulated in
human and mouse HD brains in vivo, and is required for a
subset of mutant Htt–induced transcriptional alterations. In
addition, we demonstrate that Twist1 is essential for mutant
Htt–induced neurotoxicity, indicating that Twist1 up-regulation is functionally important for mutant Htt– expressing neurons. In addition, using Bdnf as a model gene, we showed that
Twist1 is required for mutant Htt–induced hypermethylation
of the Bdnf promoter IV and subsequent down-regulation of
the transcript driven by this promoter. Our study thus reveals a
novel transcriptional mechanism important for mutant Htt–
induced neurotoxicity, which can potentially be targeted to
protect HD neurons.
Using HD model neurons, our findings demonstrate for the
first time the critical role of Twist1 in mutant Htt–induced
neurotoxicity. Defining the role and therapeutic potential of
Twist1 in HD in vivo using animal models represents an important future goal. In addition to attenuating Twist1 expression in
mutant Htt– expressing neurons, manipulating key down-

stream Twist1 targets may represent an alternative, and potentially more specific, means of blocking neuronal dysfunction
and death in HD. Further mechanistic studies are needed to
identify the specific Twist1 target genes that contribute to
mutant Htt–induced toxicity.
Our genome-wide RNA analysis demonstrates that Twist1
knockdown could rescue a subset of differentially expressed
genes, which are both up- and down-regulated, in mutant Htt–
expressing cortical neurons, providing evidence that Twist1
plays an important role in mutant Htt–induced transcriptional
alterations in neurons. Twist1 can activate or repress transcription of target genes by recruiting other transcriptional regulators and chromatin modifiers to the regulatory region of specific genes (40, 64 – 67, 74, 75). Interestingly, our analysis of the
ChEA database suggests that transcriptional repressors, including PRC1 and PRC2, may cooperate with Twist1 to repress
transcription of specific genes in mutant Htt– expressing neurons. Interestingly, previous studies with cancer cells and mesenchymal stem cells have suggested that Twist1 recruits PRC1
and PRC2 to target gene loci, leading to transcriptional repression (64, 66). Although these studies were performed in the
context of nonneuronal cells, it is possible that a similar mechanism plays a role in HD neurons. In future studies, identification of the neuron-specific Twist1 protein complex will help
determine how specific sets of genes are regulated in neurons
by this transcription factor.
BDNF is an important neurotrophic factor that has been
strongly implicated in the etiology of HD (23, 26, 27, 29). We
have previously shown that mutant Htt down-regulates Bdnf IV
and VI transcripts in cortical neuron cultures (21). These transcripts have also been found to be down-regulated in the brains
of HD patients and mouse models, suggesting that the reduction of these transcripts is clinically relevant (23, 26, 73). Our
findings demonstrate that Twist1 is required for down-re-
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gulation of the Bdnf IV and VI transcripts in mutant Htt–
expressing cortical neurons. Interestingly, the regulatory
region of the Bdnf exon IV has several E-box sequences
(CANNTG) that are conserved between human and mouse,

including CATATG (⫺49 to ⫺44 bp from the TSS of mouse
Bdnf exon IV), which is known to be a preferential binding
sequence for the Twist1 homodimer (61). This observation
raises the intriguing possibility that Bdnf IV may be a direct
J. Biol. Chem. (2018) 293(30) 11850 –11866
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Figure 5. Knockdown of Twist1 rescues altered expression of selected genes in mutant Htt– expressing cortical neurons. A and B, RNA-Seq analysis was
performed with primary cortical neurons co-transduced with lentivirus expressing Htt-25Q and control shRNA, Htt-72Q and control shRNA, or Htt-72Q and
Twist1 shRNA (1 or 2) (n ⫽ 4/group). RNA-Seq analysis revealed that a subset of differentially expressed genes in Htt-72Q– expressing neurons was restored by
Twist1 RNAi. Venn diagrams show that the expression of 143 down-regulated genes (A) and 53 up-regulated genes (54* genes, including Twist1) (B) in
Htt-72Q– expressing neurons (兩log2FC兩 ⬎ 0.5, FDR ⬍ 0.05) is commonly reversed by two different Twist1 shRNAs. A list of these genes can be found in Table S6.
C, from the 196 Twist1-dependent deregulated genes (143 down- and 53 up-regulated genes) identified by RNA-Seq analysis with Twist1 RNAi in A and B, 55
genes (49 down- and 6 up-regulated genes), which were shown to be differentially expressed in human and mouse HD cortices in previous RNA-profiling
studies, were selected. A heat map of the 55 genes was generated with the R package heatmap3. D, qRT-PCR analysis showed that Egr3 and Egr4 in mutant
Htt– expressing primary cortical neurons were reactivated by knockdown of Twist1 with two different Twist1 shRNAs (Egr3 (left): ANOVA; *, p ⫽ 0.0005; #, p ⫽
0.005 compared with Htt-72Q neurons with control RNAi, n ⫽ 6; Egr4 (right): ANOVA; *, p ⫽ 0.024; #, p ⫽ 0.022 compared with Htt-72Q neurons with control
RNAi, n ⫽ 5). Data represent mean ⫹ S.E. (error bars). E, enrichment of potential Twist-binding sequences (JASPAR MA0633.1) was found within 2 kb of the TSS
of the Twist1-dependent deregulated genes in mutant Htt– expressing neurons by de novo motif analysis. Among the 196 Twist1-dependent genes (143 downand 53 up-regulated genes in A and B), 63 down- and 24 up-regulated genes were found to contain potential Twist-binding sites (total 157 sites). See also Table
S7. F, KEGG pathway analysis of Twist1-dependent down-regulated genes (143 genes) identified by RNA-Seq analysis in A. Top-enriched pathways were
determined using DAVID bioinformatics resources. G, potential regulators of Twist1-dependent down-regulated genes in Htt-72Q– expressing neurons (143
genes in A) were identified using the X2K software with the ChIP-X enrichment analysis (ChEA) database. The top 10 regulators from this analysis are shown.
SUZ12, MTF2, JARID2, EZH2, and EED are the core or regulatory components of PRC2 complex. RNF2 and PHC1 are the components of PRC1 complex. A
complete list of potential regulators can be found in Table S8.
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binding target of Twist1. The specific genes dysregulated by
direct binding of Twist1 in mutant Htt– expressing neurons
remain to be determined in future studies. Together, our findings provide evidence that Twist1 plays a functionally important role in mutant Htt–induced neuronal death, probably by
altering the expression of key genes.
Our previous study demonstrated that mutant Htt–induced
down-regulation of Bdnf IV transcripts relies on DNA methylation in cortical neurons (21). In the present study, we show
that Twist1 is essential for mutant Htt–induced hypermethylation of Bdnf promoter IV. Given that cross-talk between
Twist1 and DNMT3A or DNMT3B has been observed in can-
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cer cells (65, 67), it will be interesting to test the hypothesis that
Twist1 recruits DNMTs to target loci in HD neurons.
The exact mechanism of Twist1 up-regulation in mutant
Htt– expressing neurons remains an important open question.
It is possible that mutant Htt up-regulates Twist1 by abnormally interacting with or sequestering epigenetic or transcriptional regulators of Twist1. Alternatively, mutant Htt–induced
cell signaling may influence Twist1 transcription by activating
or inactivating its upstream regulators. Our data showed that
mutant Htt increases levels of the transcriptionally active
H3K4me3 mark in the regulatory region of Twist1 in cortical
neurons. Supporting these findings, recent genome-wide inte-
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Figure 6. Twist1 knockdown blocks abnormal promoter methylation and expression of Bdnf in mutant Htt– expressing cortical neurons. A, DIV 5
cortical neurons were co-transduced with lentivirus expressing Htt and Twist1 shRNA (1 or 2) or control luciferase (Ctrl) shRNA. Five days later, RNA was prepared
and subjected to qRT-PCR. Knockdown of Twist1 with the two different shRNAs restored the expression of Bdnf exon IV and exon VI transcripts (Bdnf IV (left):
ANOVA; *, p ⫽ 0.0001 compared with Htt-25Q neurons with control RNAi; #, p ⫽ 0.011 (shTwist1#1); #, p ⫽ 0.0007 (shTwist1#2) compared with Htt-72Q neurons
with control RNAi, n ⫽ 8; Bdnf VI (right): ANOVA; *, p ⫽ 0.0001 compared with Htt-25Q neurons with control RNAi; #, p ⫽ 0.0002 (shTwist1#1); #, p ⫽ 0.0003
(shTwist1#2) compared with Htt-72Q neurons with control RNAi, n ⫽ 8). B, DIV 5 cortical neurons transduced with Htt– expressing lentivirus were treated
with FdCyd or DMSO (vehicle). Five days later, RNA was prepared and subjected to qRT-PCR analysis. The Twist1 RNA levels in Htt-72Q– expressing
neurons were not significantly altered by FdCyd treatment (n ⫽ 4). C, genomic DNA was purified from primary cortical neurons transduced as in A at 5
days after infection and was subjected to MeDIP with anti-5-mC antibody followed by qPCR. The increased levels of 5-mC were found in the Bdnf exon
IV promoter of Htt-72Q– expressing neurons compared with that of Htt-25Q neurons (ANOVA; *, p ⫽ 0.047, n ⫽ 8), and knockdown of Twist1 with two
different Twist1 shRNAs (1 and 2) could inhibit the increase in Bdnf promoter IV methylation in Htt-72Q– expressing neurons (ANOVA; #, p ⫽ 0.0264
(Twist1 shRNA 1); #, p ⫽ 0.012 (Twist1 shRNA 2) compared with Htt-72Q plus control shRNA, n ⫽ 8). D, a model for the role of Twist1 in mutant
Htt–induced down-regulation of Bdnf in neurons. Twist1 is up-regulated by mutant Htt and triggers down-regulation of Bdnf in mutant Htt– expressing
cortical neurons. The increased levels of H3K4me3 are associated with Twist1 up-regulation (Fig. 4K). Twist1 is required for increased DNA methylation
at Bdnf promoter IV. Whether Twist1-dependent promoter methylation is a general mechanism for other genes repressed by mutant Htt remains to be
determined. Data represent mean ⫹ S.E. (error bars) (A–C).
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Experimental procedures
Antibodies and reagents
Mouse monoclonal anti-Twist1 (Twist2C1a, sc-81417, Santa
Cruz Biotechnology, Inc.) and anti-␤-actin (sc-47778, Santa
Cruz Biotechnology) antibodies were used for immunoblotting.
Mouse monoclonal anti-Htt antibody (MAB5492, Millipore)
was used for immunofluorescence and immunoblotting. Rabbit
monoclonal anti-H3K4me3 antibody (05-745R, clone 15-10CE4, Millipore) was used for ChIP. Mouse monoclonal anti-NF
(165 kDa) (clone 2H3, Developmental Studies Hybridoma
Bank) was used for immunofluorescence. The secondary antibody for immunofluorescence, goat-anti mouse IgG (H⫹L)
conjugated with Alexa Fluor 488 or Alexa Fluor 568, Hoechst
33342, and SYTOX Green were purchased from Thermo Fisher
Scientific. FdCyd was purchased from Sigma (F5307).
Plasmids
Lentiviral plasmids expressing Htt-25Q and Htt-72Q under
the control of the mouse PGK (Pgk1) promoter (mPGKHttex1–25Q and mPGK-Httex1–72Q) were kindly provided by
D. Krainc (Northwestern University, Chicago, IL). Twist1
RNAi and Pou4f1 RNAi lentiviral constructs (pLKO.1-puro),
developed at the Broad Institute of MIT and Harvard, were
purchased from Sigma-Aldrich. The primer sequences in
the shRNA vectors targeting Twist1 and Pou4f1 are as
follows: pLKO.1-Twist1 shRNA 1 (TRCN0000095076), CCGGGCCCTCGGACAAGCTGAGCAACTCGAGTTGCTCAGCTTGTCCGAGGGCTTTTTG; pLKO.1-Twist1 shRNA 2
(TRCN0000095077), CCGGAGCAAGATTCAGACCCTCAAACTCGAGTTTGAGGGTCTGAATCTTGCTTTTTTG;
pLKO.1-Pou4f1 shRNA 1 (TRCN0000095335), CCGGGATGAAATTCTCTGCCACTTACTCGAGTAAGTGGCAGAGAATTTCATCTTTTTG; pLKO.1-Pou4f1 shRNA 2 (TRCN
0000095337), CCGGGTACCACACGATGAATAGCGTCTCGAGACGCTATTCATCGTGTGGTACTTTTTG; pLKO.1Pou4f1 shRNA 3 (TRCN0000095338), CCGGCAGAAGCGGATGAAATTCTCTCTCGAGAGAGAATTTCATCCGCTTCTGTTTTTG.

The FLAG-tagged Twist1 rescue construct (Twist1-Res),
which harbors nine-base mismatches in the region targeted by
Twist1 RNAi (Twist1 shRNA 2) (TCTAAAATCCAAACACTGAAG, mismatches underscored), was generated by a PCRbased method, and the Twist1-Res cDNA was subcloned into
pRRLsinPGK vector.
Primary neuron cultures, lentiviral transduction, and drug
treatment
Mouse primary cortical neurons were prepared from embryonic day 15.5 Swiss Webster mouse fetuses (Taconic) and
transduced with lentivirus at DIV 5 as described previously
(21). Lentiviral particles were prepared by transfecting 293LE
cells with a lentiviral plasmid along with packaging plasmid
psPAX2 and envelope plasmid pCMV-SVG and purified from
the conditioned medium as described previously (21). Equal
numbers of viral particles of Htt-25Q– and Htt-72Q–
expressing lentiviruses were used for transduction of neurons
on the basis of viral copy number measured using the Lenti-X
qRT-PCR titration kit (Clontech). In lentivirus-mediated
knockdown experiments in Htt-expressing neurons, DIV 5 primary neurons were cotransduced with shRNA- and Htt-expressing lentiviruses. pLKO.1-luciferase shRNA was used as
control for pLKO.1-Twist1 shRNA and pLKO.1-Pou4f1
shRNA. For the experiments to test the effects of DNMT inhibitor FdCyd on Twist1 mRNA expression, neurons were treated
with the drug 6 h after Htt lentiviral infection at DIV 5. One half
of the medium was changed again at DIV 8 with the medium
containing new drug, and neurons were harvested at DIV 10 for
qRT-PCR analysis.
Measurements of cell viability, cell death, and neurite
degeneration in primary neurons
The viability of the transduced primary cortical neurons that
are grown on a 96-well plate was assessed for mitochondrial
metabolic activity at 9 days postinfection (DIV 14) using 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) per the manufacturer’s instructions. MTS-reducing activity was normalized
for each condition to Htt-25Q lentiviruses cotransduced with
control RNAi lentivirus (⫽ 1). Cell death of the transduced
primary cortical neurons at 8 days after Htt lentivirus infection
(DIV 13) was assessed using SYTOX Green (Thermo Fisher
Scientific), a fluorescent nucleic acid stain that is impermeant
to live cells. SYTOX Green was added to culture medium at a
final concentration of 0.1 M along with Hoechst 33342
(Thermo Fisher Scientific) at a final concentration of 1 g/ml.
Neurons were then incubated at 37 °C in a CO2 incubator for 15
min, and images were captured (five random fields per well)
using an Operetta high-content imaging system (PerkinElmer
Life Sciences) with a ⫻20 objective lens. The percentage of dead
cells was quantified by counting the number of SYTOX Greenpositive dead cells over total cells labeled with Hoechst using
an ImageJ-based macro. Degeneration of neurites was
assessed by the quantitative measurement of NF immunofluorescence intensity from the images captured (nine random
fields per well) using an Operetta high-content imaging sysJ. Biol. Chem. (2018) 293(30) 11850 –11866
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grated analysis of H3K4me3 and RNA expression profiles from
the cortex of R6/2 HD mice in vivo revealed increased levels of
the H3K4me3 mark at the Twist1 locus (11), suggesting a mechanism for Twist1 up-regulation in HD. These observations raise
the possibility that the activity of enzymes catalyzing H3K4me3
may be altered by mutant Htt by the mechanism(s) suggested
above. In addition, a recent study has shown that inhibition of
the histone H3 Lys-27 methyltransferase complex PRC2 in neurons in mice causes up-regulation of PRC2 target genes encoding transcription factors, including Twist1, and leads to neurodegeneration (76), suggesting that PRC2 inhibition may be
involved in the up-regulation of Twist1 in the context of mutant
Htt. However, whether PRC2 is inhibited in HD neurons
remains to be examined. Our study reveals a critical role for
Twist1 in mutant Htt–induced transcriptional dysregulation
and toxicity in neurons. As Twist1 up-regulation has also been
observed in the brains of Alzheimer’s disease patients (77), our
findings may have ramifications for other neurodegenerative
conditions.
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tem (PerkinElmer Life Sciences) with a ⫻20 objective lens as
described previously (21).

TCT; Hprt forward, TTGACACTGGTAAAACAATGCAAAC; Hprt reverse, GAGAGGTCCTTTTCACCAGCA.

HD mouse models

RNA-Seq analysis, data acquisition, quality control, and
processing

qRT-PCR
RNAs were isolated from cultured neurons 5 days after infection of Htt lentiviruses and mouse brain using the RNeasy Plus
Mini Kit (Qiagen) and RNeasy Plus Universal Mini Kit (Qiagen), respectively. Reverse transcription was performed with
the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). qPCR was performed using Power SYBR Green
PCR Master Mix (Applied Biosystems) on the CFX Connect
Real-Time System (Bio-Rad). ␤-actin was used as a reference
gene for data normalization unless otherwise stated. Relative
mRNA levels were calculated using the ⌬⌬Ct method.
Sequences of the primers used are as follows: Twist1 forward,
TAGAAGTCTGAACACTCGTT; Twist1 reverse, AATTCCTCTGATTGTTACCATT; Pou4f1 forward, CTTCACGGTTCTCCAAAGGA; Pou4f1 reverse, AGAGACAGAAGCAGAAGCGG; Egr3 forward, TTGCCTGACAATCTGTACCCC;
Egr3 reverse, TAATGGGCTACCGAGTCGCT; Egr4 forward,
TATCCTGGAGGCGACTTCTTG; Egr4 reverse, AGATGCCAGACATGAGGTTGA; Bdnf exon IX (protein coding) forward, GACAAGGCAACTTGGCCTAC; Bdnf exon IX (protein coding) reverse, CGTGCTCAAAAGTGTCAGCC; Bdnf
exon IV forward, CAGAGCAGCTGCCTTGATGTT; Bdnf
exon IV reverse, GCCTTGTCCGTGGACGTTTA; Bdnf exon
VI forward, TTGGGGCAGACGAGAAAGCGC; Bdnf exon VI
reverse, AGGATGGTCATCACTCTTCTC; Drd2 forward,
CTGGAGCCAAAAGCAGTCTG; Drd2 reverse, TCCTTCAGGTTTCCGACGCC; Ppp1r1b forward, CCAACCCCTGCCATGCTTT; Ppp1r1b reverse, TTGGGTCTCTTCGACTTTGGG; ␤-actin (Actb) forward, AGTGTGACGTTGACATCCGTA; ␤-actin (Actb) reverse, GCCAGAGCAGTAATCTCCT-
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Total RNAs were prepared from primary cortical neurons 5
days after lentiviral infection (n ⫽ 4 cultures/condition) using
the RNeasy Plus Mini Kit. The integrity of total RNA was validated by an Agilent bioanalyzer. A library was prepared from
0.5–1 g of RNA treated with the Ribo-Zero rRNA removal kit
(Epicenter) per the manufacturer’s protocol. cDNA was bluntended, an A base was added to the 3⬘ ends, and then Illumina
sequencing adapters were ligated to the ends. Ligated fragments were then amplified for 12 cycles using primers incorporating unique index tags. Fragments were sequenced on Illumina Hi-Seq-2500 or Hi-Seq-3000 using single reads extending
50 bases, targeting 25–30 million reads/sample. RNA-Seq was
performed with primary cortical neurons expressing 1) control
empty vector, 2) Htt-25Q, and 3) Htt-72Q in Fig. 1 and primary
cortical neurons expressing 1) Htt-25Q and control luciferase
RNAi, 2) Htt-72Q and control luciferase RNAi, 3) Htt-72Q and
Twist1 RNAi 1, and 4) Htt-72Q and Twist1 RNAi 2 in Fig. 5.
RNA-Seq reads were aligned to the Ensembl release 76 assembly with STAR version 2.0.4b. Gene counts were generated by
Subread:featureCount version 1.4.5, and transcript counts were
produced by Sailfish version 0.6.3. Sequencing performance
was assessed for total number of aligned reads, total number of
uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation, and read distribution over known gene models with RSeQC version 2.3. All
gene-level and transcript counts were imported into the R/Bioconductor package EdgeR, and TMM normalization size factors were calculated to adjust for samples for differences in
library size. Genes or transcripts not expressed in any sample
were excluded from further analysis. The TMM size factors and
the matrix of counts were then imported into R/Bioconductor
package Limma, and weighted likelihoods based on the
observed mean-variance relationship of every gene/transcript
were then calculated for all samples with the Voom function.
Performance of the samples was assessed with a Spearman correlation matrix and multidimensional scaling plots. Gene/transcript performance was assessed with plots of residual S.D.
deviation of every gene to their average log-count with a
robustly fitted trend line of the residuals. Generalized linear
models with robust dispersion estimates were then created to
test for gene/transcript level differential expression. An additive model was applied for the differential expression analysis.
Differentially expressed genes and transcripts were then filtered for FDR-adjusted p ⬍ 0.05. A heat map of the significant
results was generated with the R package heatmap3. Gene
Ontology and KEGG pathway analyses were performed using
the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources version 6.8 (NIAID,
National Institutes of Health) (11).
Transcriptional regulatory network analysis
Gene regulatory networks were constructed as described in a
previous study with some modifications (54). 1093 differen-

Downloaded from http://www.jbc.org/ at Washington University on November 20, 2019

R6/2 mice, which carry the promoter sequence and exon 1 of
a mutant human HTT gene, were obtained from the Jackson
Laboratory (Bar Harbor, ME) (stock no. 002810), and a colony
was maintained by breeding R6/2 males with B6CBAF1 females
(Jackson Laboratory). PCR genotyping was performed as
described previously (55). To maintain mice carrying the similar number of CAG repeats, a second PCR analysis was conducted using a primer set amplifying across the CAG repeats
(ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC and GGCGGCTGAGGAAGCTGAGGA) (78). zQ175 knock-in mice
were obtained from the Jackson laboratory (stock no. 370437;
CHDI Foundation stock 81003003) and were maintained in the
C57BL6/J background. PCR genotyping and CAG repeat length
analyses for zQ175 mice were performed as described previously (79). The CAG repeat length of R6/2 and zQ175 mice was
also determined by Laragen Inc. (Culver City, CA) using tail
DNA. The R6/2 and zQ175 mice used for experiments carried
170 ⫾ 5 repeats and 190 ⫾ 10 repeats, respectively. All live
vertebrate experiments were performed in compliance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Animal protocols were approved by the
institutional animal care and use committees of Washington
University.
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Motif analysis
The DNA sequences of promoter regions (2 kb around the
TSS) of selected genes were isolated from mouse reference
genome (mm10 assembly) and were used to perform motif
analysis. The Twist1 motif position weight matrix was obtained
from the JASPAR database (62), and FIMO (63) was used to de
novo discover the potential Twist1 binding motif based on its
position weight matrix at the stringent cutoff p value ⬍ 0.0001.
The prediction was further processed and cleaned by an inhouse transcript.
MeDIP
Genomic DNA was isolated from primary cortical neurons
using QIAamp DNA Mini Kit (Qiagen) and fragmented by sonication using Bioruptor (Diagenode). 5-mC– containing DNA
fragments were enriched from 1 g of the sonicated genomic
DNA by immunoprecipitation (IP) with mouse monoclonal
anti-5mC antibody (Eurogentec, catalog no. BI-MECY-0100) as
described previously (21). IP and 10% input DNA samples were
purified using the MinElute PCR purification kit (Qiagen) and
subjected to qPCR with Bdnf promoter IV and Gapdh (internal
control) primers to measure the enrichment of the DNA fragment containing the Bdnf promoter IV region. The percentage
input was calculated by normalizing IP to input DNA using the
formula, 2((Ct(10% input) ⫺ 3.32) ⫺ Ct(IP)) ⫻ 100, as described previously (80). The sequences of the primers used are as follows:
MeDIP-Bdnf IV forward, GCGCGGAATTCTGATTCTGGTA; MeDIP-Bdnf IV reverse, CTGCCTTGACGTGAGCTGTC; Gapdh forward, CTCTGCTCCTCCCTGTTCC; Gapdh
reverse, TCCCTAGACCCGTACAGTGC. The MeDIP-Bdnf
IV primer set amplifies the region, ⫺112 to ⫺25 bp from the
TSS, of the mouse Bdnf promoter IV.
ChIP-qPCR
Mouse primary cortical neurons were subjected to
ChIP assay with anti-H3K4me3 rabbit mAb (Millipore 05-

745R; clone 15-10C-E4). ChIP was performed as described
previously (81). The percentage input was calculated as
2((Ct(10% input) ⫺ 3.32) ⫺ Ct(IP)) ⫻ 100 and compared between WT
and mutant Htt– expressing neurons. Sequences of the primers
used for qPCR are as follows: mTwist1 promoter forward,
GAAAAGTCCCTCCTCCCCAC; mTwist1 promoter reverse,
GTGGACTTGGCGGCTCTTAT; mTwist1 exon 1 forward,
CCGCCCGCGAGATGATG; mTwist1 exon 1 reverse,
CTGTTGCTCAGGCTGTCGTC.
Preparation of brain lysates
Mouse brain lysates were prepared in TNE buffer (10 mM
Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40)
containing protease inhibitors and phosphatase inhibitors
using a Dounce homogenizer. Because the anti-Twist1 antibody used for immunoblotting was a monoclonal mouse IgG,
we precleared the lysates with Dynabeads protein G (Thermo
Fisher Scientific) to remove endogenous IgG from brain tissues
before using them for immunoblotting.
Statistical analysis
Statistical differences were tested using GraphPad Prism version 7.0. Two-tailed unpaired Student’s t test was used for comparisons between two groups. For the experiments with more
than two groups, one-way ANOVA was performed, followed by
post hoc tests, Fisher’s least significant difference for comparison among three groups, and Bonferroni’s or Dunnett’s test for
comparison among three or more than three groups. The data
presented are from at least three independent experiments.
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